Mr. Gustafson has more than 25 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations. Mr. Gustafson currently serves as chief financial officer of OmniAb. Previously, he served as chief financial officer Spectrum Pharmaceuticals, Inc., and prior to that, he served as chief financial officer at Halozyme Therapeutics, Inc., where he managed several successful financings and established a three-year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years, most recently as vice president, finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as treasurer, vice president, finance and chief financial officer of Amgen International based in Switzerland. Mr. Gustafson holds a B.A. degree in accounting from North Park University in Chicago and an M.B.A. from University of California, Los Angeles.